{"id":"telbivudine-roadmap","safety":{"commonSideEffects":[{"rate":null,"effect":"Myopathy"},{"rate":null,"effect":"Elevated creatine kinase"},{"rate":null,"effect":"Lactic acidosis"},{"rate":null,"effect":"Hepatitis flare"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL374731","moleculeType":"Small molecule","molecularWeight":"242.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Telbivudine is a thymidine nucleoside analog that is phosphorylated intracellularly and incorporated into viral DNA, causing chain termination and inhibiting HBV reverse transcriptase. This prevents the synthesis of viral DNA and reduces viral load in patients with chronic hepatitis B infection.","oneSentence":"Telbivudine is a nucleoside reverse transcriptase inhibitor that blocks viral reverse transcriptase to inhibit hepatitis B virus replication.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:38:26.141Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B infection"}]},"trialDetails":[{"nctId":"NCT01379508","phase":"PHASE4","title":"Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-03-21","conditions":"Chronic Hepatitis B","enrollment":241},{"nctId":"NCT01521975","phase":"PHASE4","title":"A Two-year Study of Telbivudine in HBeAg Negative Hepatitis","status":"COMPLETED","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2011-01-01","conditions":"Hepatitis B, Chronic","enrollment":360},{"nctId":"NCT01529255","phase":"PHASE4","title":"EFFORT Extension Study","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2011-08","conditions":"Hepatitis B, Chronic","enrollment":576},{"nctId":"NCT00651209","phase":"PHASE4","title":"A Single-arm Study Evaluating the Efficacy and Safety of Telbivudine With or Without add-on Tenofovir in Adults With HBeAg-positive Chronic Hepatitis B (CHB)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-02","conditions":"Hepatitis B, Chronic","enrollment":105},{"nctId":"NCT00962533","phase":"PHASE4","title":"EFFicacy Optimization Research of Telbivudine Therapy","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2009-08","conditions":"Hepatitis B, Chronic","enrollment":606},{"nctId":"NCT01588912","phase":"PHASE4","title":"Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir","status":"UNKNOWN","sponsor":"Pusan National University Yangsan Hospital","startDate":"2012-04","conditions":"Chronic Hepatitis B","enrollment":104}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"telbivudine (ROADMAP)","genericName":"telbivudine (ROADMAP)","companyName":"Nanfang Hospital, Southern Medical University","companyId":"nanfang-hospital-southern-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Telbivudine is a nucleoside reverse transcriptase inhibitor that blocks viral reverse transcriptase to inhibit hepatitis B virus replication. Used for Chronic hepatitis B infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}